Loading...
Loading...
Regen BioPharma Inc
Regen BioPharma Inc. Spoken Alpha tracks RGBPP's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks RGBPP's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RGBPP.
curl https://api.spokenalpha.com/v1/companies/RGBPP| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.85 | $2.25 | -17.9% | +0.4% | 0.0% |
| Q4 FY2026 | $1.90 | $2.23 | -14.6% | -7.3% | -8.1% |
| Q3 FY2026 | $1.90 | $2.29 | -17.2% | -2.9% | -0.8% |
| Q2 FY2026 | $2.11 | $2.31 | -8.8% | -0.6% | -3.1% |
| Q1 FY2025 | $1.88 | $2.24 | -16.2% | -1.8% | +0.7% |
| Q4 FY2025 | $2.23 | $2.45 | -9.0% | -3.2% | -4.4% |
| Q3 FY2025 | $2.08 | $2.46 | -15.4% | -5.7% | -5.8% |
| Q2 FY2025 | $2.10 | $2.26 | -7.3% | +3.6% | +2.7% |
| Q1 FY2024 | $2.26 | $2.41 | -6.1% | +1.7% | -0.5% |
| Q4 FY2024 | $1.87 | $2.27 | -17.5% | -1.4% | -0.6% |